HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China

HUYA holds exclusive rights to chidamide as HBI-8000 ex-China

San Diego, CA, USA – January 12, 2015 –HUYA Bioscience International (HUYA) announced today that Shenzhen Chipscreen Biosciences (Chipscreen) has obtained marketing approval from the Chinese FDA for the world’s first oral HDAC inhibitor, chidamide, for the treatment of relapsed or refractory peripheral T-cell lymphoma.  Chidamide (Epidaza®) is an orally bioavailable, benzamide-class small molecule, that selectively inhibits cancer-associated HDAC (histone deacetylase) enzymes.  Chidamide has anti-tumor activity through various mechanisms of action, including epigenetic reprogramming and immunomodulation.  HUYA has exclusive rights to chidamide (HBI-8000) worldwide, excluding China, and is developing HBI-8000 for the treatment of hematological and solid tumors. Read more

HUYA Bioscience International Is The First To Leverage Tripartite Cooperation

PMDA accepts accelerated development strategy for HBI-8000, a novel cancer drug

San Diego, CA, USA – January 8, 2015 –HUYA Bioscience International (HUYA) announced today that the Pharmaceutical and Medical Devices Agency (PMDA) has accepted its accelerated development strategy for the novel cancer drug HBI-8000. HUYA is developing HBI-8000 for the treatment of adult T-cell leukemia/lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) in Japan. Read more